Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Xeris Biopharma Holdings, Inc. has received an average analyst rating of "Moderate Buy" from seven covering analysts, with five recommending a buy, one a hold, and one a sell.
• Recent target price updates include a boost from Leerink Partners to $9.00 and a downgrade by Wall Street Zen from "strong-buy" to "buy."
• Director Dawn Halkuff sold 42,500 shares at $7.28 each, reducing their stake by 26.98%, while another director, Jeffrey W. Sherman, also sold shares, marking significant insider activity.

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) have earned an average rating of "Moderate Buy" from the seven analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $7.0833.

Several analysts have commented on XERS shares. HC Wainwright started coverage on shares of Xeris Biopharma in a research report on Tuesday, August 12th. They issued a "buy" rating and a $10.00 target price for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Xeris Biopharma in a research report on Saturday, September 27th. Leerink Partners boosted their target price on shares of Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 19th. Finally, Wall Street Zen downgraded shares of Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a report on Friday, September 5th.

Insider Activity at Xeris Biopharma

In other news, Director Dawn Halkuff sold 42,500 shares of the stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $7.28, for a total value of $309,400.00. Following the completion of the transaction, the director owned 115,000 shares in the company, valued at approximately $837,200. This represents a 26.98% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey W. Sherman sold 42,232 shares of the stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $7.92, for a total transaction of $334,477.44. Following the completion of the transaction, the director owned 219,188 shares of the company's stock, valued at approximately $1,735,968.96. This represents a 16.15% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 207,732 shares of company stock valued at $1,550,437. Company insiders own 4.56% of the company's stock.

Institutional Investors Weigh In On Xeris Biopharma

A number of hedge funds have recently made changes to their positions in the company. Corient Private Wealth LLC acquired a new stake in shares of Xeris Biopharma during the 2nd quarter worth about $320,000. Osaic Holdings Inc. grew its holdings in Xeris Biopharma by 9.7% during the 2nd quarter. Osaic Holdings Inc. now owns 42,709 shares of the company's stock worth $199,000 after acquiring an additional 3,774 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Xeris Biopharma by 7.6% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 32,167 shares of the company's stock worth $150,000 after acquiring an additional 2,264 shares during the last quarter. Squarepoint Ops LLC grew its holdings in Xeris Biopharma by 1,679.1% during the 2nd quarter. Squarepoint Ops LLC now owns 284,567 shares of the company's stock worth $1,329,000 after acquiring an additional 268,572 shares during the last quarter. Finally, State of Wyoming bought a new stake in Xeris Biopharma during the 2nd quarter worth about $164,000. Institutional investors and hedge funds own 42.75% of the company's stock.

Xeris Biopharma Stock Performance

Xeris Biopharma stock opened at $8.20 on Monday. The firm has a market cap of $1.32 billion, a PE ratio of -39.05 and a beta of 0.39. The firm's 50 day moving average price is $7.33 and its two-hundred day moving average price is $5.65. Xeris Biopharma has a twelve month low of $2.73 and a twelve month high of $8.51.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.02. The business had revenue of $67.71 million during the quarter, compared to the consensus estimate of $64.58 million. Equities analysts anticipate that Xeris Biopharma will post -0.41 EPS for the current fiscal year.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.